HRMY · Harmony Biosciences Holdings, Inc. · Investor Relations

PLYMOUTH MEETING, Pa. -- Sept. 22, 2026 -- Harmony Biosciences today recognized World Narcolepsy Day, observed annually on September 22, by reflecting on nearly a decade of commitment to the narcolepsy and broader sleep-wake community. Since its founding in 2017, Harmony has worked alongside

PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company’s investigation of EPX-100 (clemizole hydrochloride) at the 16 th European Epilepsy Congress being held from September 5-9,

PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20

PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET.

WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion to $1.04 Billion Phase 1 SAD Data for BP-205 Demonstrate Favorable PK and Safety/Tolerability Profiles;

PLYMOUTH MEETING, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, before the open of the U.S. financial markets.

WAKIX® Net Revenue Grew 30% Year over Year to a Record of Approximately $261 Million for Q2 2026 Reaffirms 2026 Net Revenue Guidance of $1.0 Billion to $1.04 Billion Full Q2 2026 Financial Results and Business Updates to be Reported on August 4, 2026 PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Jul.

PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Jun. 11, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that six abstracts in narcolepsy and idiopathic hypersomnia have been accepted for poster presentation at SLEEP 2026, the 40th annual meeting of the Associated Professional

PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--May 27, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat: June 9,

WAKIX® Net Revenue Grew 17% to $215.4 Million for First Quarter 2026; On Track for Full Year 2026 Net Revenues over $1 Billion Continue to Vigorously Protect WAKIX IP into 2030; Filed Suit Against AET Pharma/Sandoz Regarding Infringement of Amorphous Pitolisant Patent Lifecycle Management Advancing

PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Apr. 23, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets.

PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Apr. 16, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore open-label extension data from the company’s investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment

COMPANY REITERATES ITS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION IN WAKIX SALES PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Apr. 14, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the appointment of Glenn Reicin as Chief Financial Officer, effective immediately,

Appointments support Harmony’s next phase of growth and long‑term value creation PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Apr. 2, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of

PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Mar. 31, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that Harmony's management team will participate in a fireside chat at the upcoming 25 th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026, at 9:30 a.m.

PLYMOUTH MEETING, Pa. --(BUSINESS WIRE)--Mar. 4, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will attend the following upcoming investor conferences. Leerink Partners Global Healthcare Conference Date: March 9, 2026 Location: Miami, FL

WAKIX 2025 Net Revenue of $868.5 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy Recently Completed Settlements with 3 Additional Generic Filers Toward Goal of Securing WAKIX Franchise Pitolisant GR NDA Submission on Track for Q2 2026;